Veracyte, Inc.
HealthcareNASDAQ:VCYT · NASDAQ Global Market
-$0.09 today
Vol 1.07M · Avg 1.23M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
5.1%
avg -23.1%
ROIC
5.3%
avg -15.8%
ROA
4.7%
avg -14.2%
Analysis
ROIC is currently the strongest return metric at 5.3% versus its period average of -15.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marc A. Stapley | Chief Executive Officer & Director | $1.53M | — | 56 | $578,545.00 | 0.73% |
Phillip G. Febbo | Chief Scientific & Medical Officer | $930,089.00 | — | 60 | $149,797.00 | 0.19% |
Rebecca Chambers | Executive Vice President & Chief Financial Officer | $911,950.00 | — | 48 | $175,241.00 | 0.22% |
John Leite | Global Chief Commercial Officer | $846,485.00 | — | 54 | $132,305.00 | 0.17% |
Annie McGuire | Executive VP, General Counsel & Head of Market Access | $829,500.00 | — | 45 | $137,240.00 | 0.17% |
Steven French | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Karen Possemato | Senior Vice President of Corporate Marketing, Communications & Commercial Operations | — | — | — | — | — |
Kelly Gura | Director of Investor Relations | — | — | — | — | — |
Keith Gligorich | Senior Vice President of Global Operations | — | — | — | $116,858.00 | 0.15% |
Kevin Richard Haas | Chief Development and Technology Officer | — | — | 41 | $44,221.00 | 0.06% |
Jonathan Wygant | Vice President & Chief Accounting Officer | — | — | 55 | $44,073.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
54
$21.29M
Net Sentiment
$21.29M
Net selling
Most Active
McGuire Annie
13 transactions
1–10 of 54
Analysis
Insiders reported 0 buys worth $0.00 and 54 sells worth $21.29M over the last 12 months. That adds up to net selling of $21.29M. McGuire Annie was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +62.1% | +21.1% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +62.1% over three years. Forward estimates point to Revenue at +21.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Amicus Therapeutics, Inc.
FOLD
$4.55B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Who manages VCYT?
Veracyte, Inc. (VCYT) lists 11 active executives. The top listed executive is Rebecca Chambers, Executive Vice President & Chief Financial Officer.
Are VCYT insiders buying or selling?
Recent insider activity shows net selling of $42.77M.
Explore More
Continue the stock analysis
Jump to another research area for this company.